0000000000512894

AUTHOR

Juliette Saillard

showing 2 related works from this author

Practices in research, surveillance and control of neglected tropical diseases by One Health approaches: A survey targeting scientists from French-sp…

2021

One health (OH) approaches have increasingly been used in the last decade in the fight against zoonotic neglected tropical diseases (NTDs). However, descriptions of such collaborations between the human, animal and environmental health sectors are still limited for French-speaking tropical countries. The objective of the current survey was to explore the diversity of OH experiences applied to research, surveillance and control of NTDs by scientists from French-speaking countries, and discuss their constraints and benefits. Six zoonotic NTDs were targeted: echinococcoses, trypanosomiases, leishmaniases, rabies, Taenia solium cysticercosis and leptospiroses. Invitations to fill in an online q…

http://aims.fao.org/aos/agrovoc/c_8081RC955-962Psychological interventionSocial Scienceshttp://aims.fao.org/aos/agrovoc/c_431Computer-assisted web interviewingPolitical Aspects of HealthGlobal HealthSanté publique0302 clinical medicineMedical ConditionsArctic medicine. Tropical medicineSurveys and QuestionnairesPublic and Occupational Healthhttp://aims.fao.org/aos/agrovoc/c_6970media_commonMammalsSanté animaleNeglected DiseasesEukaryota3. Good healthÉpidémiologie[SDV] Life Sciences [q-bio]http://aims.fao.org/aos/agrovoc/c_1790medicine.drug_formulation_ingredientOne Healthhttp://aims.fao.org/aos/agrovoc/c_2085Veterinary Diseases[SDE]Environmental SciencesPublic aspects of medicinehttp://aims.fao.org/aos/agrovoc/c_4027http://aims.fao.org/aos/agrovoc/c_8068http://aims.fao.org/aos/agrovoc/c_8500medicine.medical_specialtyRabiesmedia_common.quotation_subjectPolitical ScienceLeptospiroseRage03 medical and health sciencesPolitical scienceTaenia soliumhttp://aims.fao.org/aos/agrovoc/c_3081HumansSurveillance épidémiologiquehttp://aims.fao.org/aos/agrovoc/c_8530Survey ResearchPublic Health Environmental and Occupational HealthOrganismsBiology and Life SciencesTropical Diseaseshttp://aims.fao.org/aos/agrovoc/c_7558http://aims.fao.org/aos/agrovoc/c_6349http://aims.fao.org/aos/agrovoc/c_4281Veterinary ScienceDiversity (politics)[SDE] Environmental SciencesViral DiseasesBiomedical Researchhttp://aims.fao.org/aos/agrovoc/c_2615[SDV]Life Sciences [q-bio]http://aims.fao.org/aos/agrovoc/c_870SurveysL73 - Maladies des animauxhttp://aims.fao.org/aos/agrovoc/c_875http://aims.fao.org/aos/agrovoc/c_16411http://aims.fao.org/aos/agrovoc/c_7988http://aims.fao.org/aos/agrovoc/c_6416ZoonosesTrypanosomoseMedicine and Health Sciences030212 general & internal medicinehttp://aims.fao.org/aos/agrovoc/c_3423http://aims.fao.org/aos/agrovoc/c_5164http://aims.fao.org/aos/agrovoc/c_4510http://aims.fao.org/aos/agrovoc/c_16415EchinococcoseInfectious DiseasesResearch DesignS50 - Santé humaineVertebrateshttp://aims.fao.org/aos/agrovoc/c_7979Neglected tropical diseasesRA1-1270Zone tropicaleResearch ArticleNeglected Tropical Diseaseszoonosehttp://aims.fao.org/aos/agrovoc/c_28665030231 tropical medicineMEDLINEResearch and Analysis Methodshttp://aims.fao.org/aos/agrovoc/c_259http://aims.fao.org/aos/agrovoc/c_35197DogsEnvironmental healthTropical MedicinemedicineLeishmanioseAnimalsCysticercosehttp://aims.fao.org/aos/agrovoc/c_5181Enquête pathologique[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieTropical medicineAmniotes[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieZoology
researchProduct

Remdesivir for the Treatment of Hospitalised Patients with COVID-19 (DisCoVeRy): A Randomised, Controlled, Open-Label Trial

2021

Background: The antiviral efficacy of remdesivir is still controversial. We aimed at evaluating its clinical effectiveness in patients with COVID-19 requiring oxygen and/or ventilator support. Methods: In this European multicentre, open-label, parallel-group, randomised, controlled trial in adults hospitalised with COVID-19 (DisCoVeRy, NCT04315948; EudraCT2020-000936-23), participants were randomly allocated to receive usual standard of care alone or in combination with intravenous remdesivir (200 mg on day 1, then 100 mg once-daily for 9 days or until discharge). Treatment assignation was performed via web-based randomisation stratified on illness severity and administrative European regio…

education.field_of_studymedicine.medical_specialtybusiness.industryPopulationDeclarationCommissionTreatment and control groupsInformed consentFamily medicineHealth caremedicinemedia_common.cataloged_instanceEuropean unioneducationbusinessPsychology[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyDeclaration of Helsinkimedia_commonSSRN Electronic Journal
researchProduct